IGF pathway has been recognized as a potential therapeutic target in FXS (Vahdatpour et al., 2016; Wise, 2017) and our studies support the hypothesis based on studies of mice, but also urge attention to possible individual variation in drug responses. The gene discussed is IGF1; the disease is fragile X syndrome.